|
|
Hemosphere Receives CE Mark Approval for the HeRO(R) Graft - MarketWatch (press release) |
MarketWatch (press release)
The HeRO Graft is an alternative to catheters for ESRD hemodialysis "catheter-dependent" patients with central venous stenosis -- a blockage of the central veins that inhibits blood flow. Since its introduction, over 4000 hemodialysis patients have
|
|
|
Keryx Biopharmaceuticals Announces Upcoming Corporate Presentations - MarketWatch (press release) |
MarketWatch (press release)
Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel,
|
|
Pathfinder, LLC and SyntheMed, Inc. Complete Merger - MarketWatch (press release) |
MarketWatch (press release)
In preclinical studies, PCs demonstrate the unique ability to reverse cell damage caused by diabetes, renal diseases and myocardial infarction. They may also be effective in other diseases characterized by organ-specific cellular damage.
|
|
Reata Pharmaceuticals - 2011 Fierce 15 - FierceBiotech |
FierceBiotech
Researchers are recruiting 1600 patients with advanced kidney disease and Type 2 diabetes with an eye to demonstrating that bardoxolone can extend the amount of time they can live without being forced onto dialysis. A distinct advantage is that
|
|
Horizon Pharma Receives US Patent Allowance for DUEXIS(R) (Ibuprofen/Famotidine) - MarketWatch (press release) |
MarketWatch (press release)
Long-term administration of NSAIDs, including ibuprofen, which is a component of DUEXIS tablets, has resulted in renal papillary necrosis and other renal injury. Use DUEXIS with caution in patients at risk (eg, the elderly; those with renal impairment,
|
|
|
|
|
<< Start < Prev 711 712 713 714 715 716 717 718 719 720 Next > End >>
|
|
Page 717 of 2630 |
Log in to explore the world's most comprehensive database of dialysis centres for free! 
Professional dialysis recruitment
